Eniporide hydrochloride (EMD-96785 hydrochloride) is a potent inhibitor of the sodium/hydrogen (Na+/H+) exchange process.

The Na+/H+ exchange inhibitor eniporide does not significantly impact cardiac performance or high-energy phosphate content in healthy pig hearts undergoing ischemia/reperfusion induced by crystalloid cardioplegic arrest [1].

In the initial phase, administering 100 mg and 150 mg of eniporide led to reduced infarct sizes, notably within the angioplasty group. However, the subsequent phase showed no variation in the enzymatic infarct sizes among the three groups. Despite these findings, eniporide had no impact on clinical outcomes, including death, cardiogenic shock, heart failure, and severe arrhythmias. Noteworthy is the substantial decrease in heart failure incidence in patients who received late reperfusion (after more than 4 hours) [2].